A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

Phase 2 Completed 932 enrolled ModernaTX, Inc.

RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.

Timeline

Start: 2024-07-15
Primary completion: 2025-09-25
Completion: 2025-09-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	mRNA-1083	Messenger RNA (mRNA)	—	Intramuscular

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

Summary

Timeline

Drugs

Indications